AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

ANTIMICROBIAL RESISTANCE:MECHANISMS, CONSEQUENCES, AND COUNTERMEASURESA CRITICAL APPRAISAL OF RESISTANCE BIOLOGY AND EMERGING THERAPEUTIC FRONTIERS

Shivprasad Sanjay Dhage

Assistant Professors

Department of Folk Medicine and Pharmacology and

Microbiology, Virology and Immunology

Fergana Medical Institute of Public Health,

Yangi Turon- 2A, Ferghana-150100,

https://doi.org/10.5281/zenodo.20142017

Abstract: Few crises in contemporary medicine carry the scope or urgency of antimicrobial resistance. Decades of unrestricted antibiotic deployment — in hospitals, community clinics, livestock operations, and aquaculture — have imposed a relentless evolutionary pressure on bacterial populations, yielding strains whose survival repertoire now routinely outpaces the drugs designed to eliminate them. Mortality attributable to resistant infections already surpasses one million deaths annually worldwide, a burden that epidemiological modelling suggests could multiply several-fold within a generation if present trajectories continue unchecked.

This review was written to provide a thorough, critically reasoned synthesis of where the field stands. We begin by mapping the epidemiological footprint of resistance across world regions and healthcare contexts, then proceed to a detailed molecular examination of the biological mechanisms through which bacteria thwart antimicrobial agents — from the catalytic destruction of drug molecules to the architectural remodelling of target proteins, from the molecular pumps that purge drugs before they can act to the dormant cell populations that simply wait out antibiotic storms. Particular attention is given to the genomic infrastructure — plasmids, integrons, and transposable elements — that allows resistance traits to cross species lines with startling speed.

Against this mechanistic backdrop, we survey the most promising therapeutic directions that researchers and clinicians are now pursuing: reformulated and structurally novel antibiotics, combination regimens built around adjuvant compounds that neutralise resistance machinery, nanoparticle delivery platforms that ferry drugs past biofilm barriers, bacteriophage-based treatments that exploit viruses as precision bacterial predators, membrane-disrupting antimicrobial peptides, CRISPR nuclease systems repurposed as sequence-directed antibacterials, and the rapidly maturing contribution of machine-learning algorithms to drug identification and resistance forecasting. We conclude by addressing the systemic obstacles — economic, regulatory, and political — that continue to slow progress, and we outline the coordinated, cross-disciplinary response that the magnitude of this challenge demands.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Keywords: antimicrobial resistance; beta-lactamase; efflux pumps; horizontal gene transfer; biofilm; persister cells; phage therapy; nanoparticle drug delivery; CRISPR antimicrobials; antimicrobial peptides; stewardship; machine learning; multidrug resistance; ESKAPE pathogens; carbapenem resistance; plasmid-mediated resistance; host-directed therapy; resistome; One Health; surveillance genomics

1. Introduction

When Howard Florey's Oxford team translated Alexander Fleming's mould-derived observations into a purified injectable preparation during the early 1940s, they could scarcely have envisioned that the very success of their work would sow the seeds of one of medicine's most enduring predicaments. Penicillin, and the cascade of antibiotic classes that followed over the subsequent four decades, fundamentally rewrote the human relationship with bacterial infection. Conditions that had been reliably fatal — bacterial meningitis, pneumococcal pneumonia, streptococcal sepsis — became manageable with short courses of inexpensive oral or intravenous drugs. Surgical procedures, organ transplantation, and cytotoxic chemotherapy, all of which create prolonged windows of immune vulnerability, became viable precisely because prophylactic and empirical antibiotic coverage could hold opportunistic pathogens in check.

That golden era of antibiotic discovery, stretching roughly from 1940 to 1980 and yielding most of the drug classes still in clinical use today, gave way to a sustained drought. After the introduction of fluoroquinolones and carbapenems in the late twentieth century, genuinely new antibiotic scaffolds reaching patients became vanishingly rare. Meanwhile, patterns of prescribing that paid little heed to diagnostic precision, combined with the indiscriminate application of antibiotics as growth promoters in food-animal husbandry, maintained a relentless selective environment in which resistant mutants and mobile resistance elements could proliferate. Resistance is not a modern invention — beta-lactamase genes have been isolated from permafrost sediments predating any clinical antibiotic use — but the pace at which resistance determinants now accumulate within clinically important lineages is a direct product of human behaviour.

The consequences are now clinical reality rather than future projection. Carbapenem-resistant Klebsiella pneumoniae isolates carrying New Delhi metallo-beta-lactamase (NDM) genes circulate on six continents. Methicillin-resistant Staphylococcus aureus (MRSA) accounts for a disproportionate share of bloodstream infections in intensive care units globally. Extensively drug-resistant tuberculosis renders the treatment of one of history's most lethal infections dependent on toxic second-line agents with cure rates a fraction of those seen for drug-susceptible disease. The ESKAPE group of pathogens — Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species — has become a shorthand for the organisms that dominate hospital-acquired infection surveillance and simultaneously resist a widening proportion of the available therapeutic arsenal.

The interconnected nature of resistance spread demands conceptual frameworks that transcend the boundaries of human medicine. The One Health paradigm — recognising that human, animal, and environmental health are inextricably linked — has become central to international policy on antimicrobial resistance. Resistance genes circulating in livestock, aquaculture systems, agricultural soils, and surface water bodies constitute an environmental reservoir from which clinical pathogens can recruit new resistance determinants. This ecological

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

dimension of resistance dissemination means that surveillance and containment efforts confined to clinical settings capture only a fraction of the problem.

Into this landscape, the pharmaceutical industry has retreated rather than advanced. Poor financial returns, compressed exclusivity periods driven by resistance emergence, and the scientific difficulty of identifying druggable bacterial targets not yet neutralised by existing resistance mechanisms have caused most large pharmaceutical companies to exit antibiotic development entirely. The burden of innovation has shifted to smaller biotechnology firms and academic consortia, many of which lack the capital to carry a candidate through the full clinical trial pathway. The result is a structural mismatch between the speed of resistance evolution and the pace of therapeutic replenishment. This review addresses that mismatch head on, tracing the molecular grammar of resistance from gene to phenotype, and evaluating the scientific foundations and practical limitations of each major countermeasure under investigation.

2. Epidemiological Dimensions of Antimicrobial Resistance



AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Figure 1. Global distribution of antimicrobial resistance burden, with hotspot regions concentrated across South Asia, Southeast Asia, sub-Saharan Africa, and parts of Latin America.

Quantifying the global burden of antimicrobial resistance with precision remained elusive for much of the early twenty-first century, largely because national surveillance systems varied enormously in scope, methodology, and geographic coverage. A systematic analysis published in The Lancet in 2022, drawing on data from 204 countries and covering 23 pathogens and 88 pathogen-drug combinations, provided the most comprehensive mortality estimate to date: directly attributable deaths of approximately 1.27 million in 2019 alone, with resistance listed as an associated cause in a further 3.68 million fatalities. These figures place antimicrobial resistance among the leading infectious causes of death worldwide, surpassing HIV/AIDS and malaria in absolute mortality in several regional analyses.

Geographically, the burden is far from uniform. Sub-Saharan Africa and South Asia together accounted for the majority of attributable deaths in that 2019 analysis, a pattern reflecting the compounding effects of high underlying infectious disease burden, limited microbiological laboratory capacity, restricted diagnostic availability, and regulatory environments that permit over-the-counter antibiotic sales without prescription. In contrast, high-income settings report lower per-capita mortality but face their own distinctive challenges: highly resistant hospital-acquired infections occurring against a backdrop of elderly, immunocompromised patient populations, and healthcare systems whose procedural complexity depends on reliable prophylactic antibiotic cover. The transnational dimension of resistance — spread through international travel, global food supply chains, and healthcare tourism — means that containment measures restricted to individual countries or regions are inherently insufficient.

In economic terms, the costs associated with resistant infections cascade through multiple domains. Direct healthcare expenditure rises because resistant infections demand longer hospital stays, more expensive or more toxic alternative antibiotics, and more intensive nursing and monitoring. A RAND Europe analysis commissioned by the UK government estimated that inadequate management of the resistance crisis could shave between 2% and 3.5% from global GDP by 2050, representing tens of trillions of US dollars. In the United States, the Centers for Disease Control and Prevention's 2019 threat assessment catalogued over 2.8 million antibiotic-resistant infections annually and attributed more than 35,000 deaths directly to resistance, with associated healthcare costs running to tens of billions of dollars each year.

The organisms attracting the greatest clinical and surveillance attention are those for which last-resort treatment options are vanishing. Carbapenem-resistant Enterobacteriaceae (CRE), pan-drug-resistant Acinetobacter baumannii, and extensively drug-resistant Pseudomonas aeruginosa represent categories for which the treating clinician may face a laboratory report offering no susceptible drug from the standard panel. The WHO's 2017 priority pathogen list formalised this hierarchy of concern, placing carbapenem-resistant and third-generation-cephalosporin-resistant gram-negative bacteria in its critical tier, followed by vancomycin-resistant Enterococcus, MRSA, and clarithromycin-resistant Helicobacter pylori in the high-priority category.

Longitudinal surveillance data collected through platforms such as the Global Antimicrobial Resistance and Use Surveillance System (GLASS) have confirmed that resistance prevalences for key pathogen-drug combinations are increasing in virtually all reporting regions, with particularly rapid escalation observed for third-generation cephalosporin resistance in E. coli and K. pneumoniae across South and Southeast Asia. Resistance in Neisseria gonorrhoeae — an

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

organism for which each successive first-line treatment has eventually been rendered ineffective — represents a microcosm of the broader challenge: the bacterium has acquired resistance to sulphonamides, penicillins, tetracyclines, fluoroquinolones, and older macrolides in sequence, and reports of reduced susceptibility to extended-spectrum cephalosporins now place the prospect of untreatable gonorrhoea firmly within the clinical horizon.

Table 1. WHO Priority Pathogen List — Selected Clinically Critical Organisms

Priority Tier	Organism	Primary Resistance Phenotype	Predominant Infection Type
Critical	A. baumannii	Carbapenem-resistant (CRAB)	HAP, VAP, wound, bloodstream
Critical	P. aeruginosa	Carbapenem-resistant (CRPA)	HAP, UTI, burns, cystic fibrosis
Critical	Enterobacteriaceae	Carbapenem/3GC-resistant (CRE/ESBL)	UTI, BSI, intra-abdominal
High	S. aureus	Methicillin-resistant (MRSA)	Skin, bone, endocarditis, BSI
High	H. pylori	Clarithromycin-resistant	Peptic ulcer, gastric malignancy
High	Salmonella spp.	Fluoroquinolone-resistant	Enteric fever, gastroenteritis
High	N. gonorrhoeae	Fluoroquinolone/3GC-resistant	Sexually transmitted infection
Medium	S. pneumoniae	Penicillin-non-susceptible	CAP, meningitis, otitis media

HAP = hospital-acquired pneumonia; VAP = ventilator-associated pneumonia; UTI = urinary tract infection; BSI = bloodstream infection; 3GC = third-generation cephalosporin; CAP = community-acquired pneumonia.

3. Classification of Resistance Phenotypes

3.1 Resistance Inherent to the Species

Certain bacterial species possess an unalterable, genetically encoded insusceptibility to particular drug classes that owes nothing to prior antibiotic exposure and cannot be reversed by

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

removing selective pressure. This intrinsic resistance is a fixed property of the organism's core genome, arising from fundamental features of its biology. Gram-negative bacteria are naturally impervious to vancomycin not because they have acquired protective genes but because vancomycin acts on the extracellular face of the peptidoglycan layer and the outer membrane physically prevents the drug from reaching its target. Pseudomonas aeruginosa is innately resistant to many antibiotic classes owing to the unusually low permeability of its outer membrane, the constitutive activity of chromosomally encoded efflux systems, and the presence of broad-spectrum beta-lactamases whose basal expression level, even before any induction, confers a degree of insusceptibility that clinical dosing cannot routinely overcome. Mycoplasma species, devoid of a cell wall, are completely unaffected by any agent targeting peptidoglycan synthesis. Recognising intrinsic resistance patterns is practically important because it establishes which drug-organism pairings should never be prescribed regardless of susceptibility report formatting.

3.2 Resistance Acquired Through Genetic Change

When a bacterium that previously responded to a given antibiotic gains the capacity to withstand it, acquired resistance has occurred. This can happen through two fundamentally distinct genetic routes. The first involves spontaneous chromosomal mutation — an error in DNA replication that, by chance, alters the structure of a drug target, boosts the expression of an efflux pump, or disrupts a porin gene, thereby reducing intracellular drug accumulation. Such mutations are random rather than directed, but in the presence of antibiotic concentrations that kill susceptible cells while permitting survival of slightly less susceptible variants, resistant clones expand rapidly. Stepwise accumulation of multiple mutations can drive minimal inhibitory concentrations (MICs) far above clinically achievable drug concentrations.

The second route, horizontal gene transfer (HGT), is arguably of greater clinical consequence because it allows resistance traits to spread far beyond the clonal descendants of an original mutant. Bacteria can acquire new genetic material from unrelated donors through conjugation, transformation, and transduction. Conjugation — the most epidemiologically significant mechanism — involves physical cell-to-cell contact during which a plasmid, together with its cargo of resistance genes, passes through a proteinaceous pilus into a recipient cell. A single conjugative event can simultaneously confer resistance to multiple antibiotic classes if the plasmid carries a diverse array of resistance determinants, a phenomenon that accounts for the seemingly sudden emergence of broadly resistant phenotypes. Transformation, the uptake of naked DNA from the environment, is particularly relevant for naturally competent species such as Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. Transduction, mediated by bacteriophages that inadvertently package host DNA during their replication cycle, provides yet another avenue for inter-strain genetic exchange that does not require direct physical contact between donor and recipient cells.

3.3 Adaptive Resistance

Adaptive resistance occupies an important and sometimes underappreciated middle ground between the stable genotypic changes described above and ordinary susceptibility. Triggered by specific environmental cues — subinhibitory antibiotic concentrations, osmotic stress, nutrient limitation, or exposure to host immune mediators — adaptive resistance involves the rapid, reversible upregulation of resistance mechanisms that revert to baseline once the stimulus disappears. Efflux pump overexpression, LPS modification reducing surface charge, and activation of global stress regulons such as the SOS response are among the responses elicited.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Clinically, adaptive resistance is concerning because it can bridge the gap between conventional susceptibility and stable genotypic resistance: bacteria surviving an adaptive response are more likely to accumulate the additional mutations needed for durable resistance, effectively using transient tolerance as a stepping stone. The SOS response, in particular, upregulates error-prone DNA polymerases that dramatically increase mutation rates, creating a mutagenic burst precisely when bacteria are under antibiotic stress — a self-reinforcing cycle that accelerates resistance evolution.

3.4 Severity Grading: MDR, XDR, and PDR

The terms multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) have been formally defined by a joint European CDC and US CDC expert working group to enable consistent cross-institutional and international reporting. An MDR organism is one found to be non-susceptible to at least one representative agent from at least three distinct antimicrobial categories. XDR designates an isolate retaining susceptibility to agents in only one or two categories, meaning that nearly all clinical options are foreclosed. PDR — the most alarming designation — is reserved for organisms showing no susceptibility to any tested agent in any category. Organisms crossing the PDR threshold confront the clinician with a situation for which no licensed antimicrobial is reliably active, making infectious disease management dependent on compassionate use of experimental agents, off-label drug combinations, or non-antibiotic approaches. The epidemiological tracking of MDR, XDR, and PDR organisms requires standardised definitions not only for clinical management but for meaningful comparison of resistance burden across institutions and geographies.

4. Molecular Mechanisms Underlying Resistance Phenotypes



AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Figure 2. Principal molecular mechanisms of bacterial antibiotic resistance: enzymatic drug inactivation, active efflux, target site modification, and decreased membrane permeability.

The biochemical and structural strategies through which bacteria neutralise antibiotics are both diverse and ingenious, reflecting evolutionary pressures that predate clinical medicine by hundreds of millions of years. Natural antibiotic compounds — many of them produced by soil bacteria and fungi as competitive weapons — have been present in microbial ecosystems since long before the pharmaceutical era, and the resistance mechanisms encoded in bacterial genomes represent a pre-existing defensive repertoire that human antibiotic use has selected for, amplified, and disseminated. Understanding each major mechanism at the molecular level is not merely an academic exercise; it is the prerequisite for rational design of drugs and adjuvants capable of circumventing them.

Table 2. Resistance Mechanisms, Representative Determinants, and Clinical Impact

Mechanism	Representative Gene/Enzyme	Drug Classes Affected	Clinical Significance
Enzymatic inactivation	KPC, NDM, OXA-48 (carbapenemases)	All beta-lactams including carbapenems	Critical — renders last-resort drugs inactive
Enzymatic inactivation	TEM, SHV, CTX-M (ESBLs)	Penicillins, cephalosporins	High — widespread in Enterobacteriaceae globally
Target modification	mecA/PBP2a (MRSA)	All beta-lactams	Critical — backbone of MRSA resistance
Target modification	gyrA/parC mutations	Fluoroquinolones	High — limits empirical therapy for UTI, pneumonia
Efflux overexpression	MexAB-OprM, AcrAB-TolC	Multiple drug classes simultaneously	High — drives MDR phenotypes in gram-negatives
Porin loss	OmpK35/36, OprD deletion	Beta-lactams, carbapenems	High — synergises with carbapenemases for PDR
Biofilm	Exopolysaccharide	All antibiotics (100-	Critical —

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Mechanism	Representative Gene/Enzyme	Drug Classes Affected	Clinical Significance
formation	matrix	1000x MIC increase)	device-associated infections uncurable without removal
Persistence	HipA/HipB, MazEF toxin-antitoxin	All antibiotics	High — underlies chronic/relapsing infections

4.1 Antibiotic Destruction by Bacterial Enzymes

The chemical neutralisation of an antibiotic molecule before it reaches its bacterial target represents perhaps the most direct and efficient resistance strategy available to bacteria. Beta-lactamases, which cleave the four-membered beta-lactam ring common to penicillins, cephalosporins, carbapenems, and monobactams, are the paradigmatic example of this class of enzyme. First identified in a clinical Staphylococcus aureus isolate just months before penicillin entered widespread use in World War II, beta-lactamases have undergone spectacular evolutionary diversification over the ensuing decades. More than 2,800 distinct variants are now catalogued, classified by the Ambler scheme into serine-based enzymes (classes A, C, and D) and zinc-dependent metallo-beta-lactamases (class B).

Extended-spectrum beta-lactamases (ESBLs), derived predominantly from the TEM, SHV, and CTX-M enzyme families through point mutations expanding their substrate range, are now virtually ubiquitous in hospital Enterobacteriaceae worldwide and are increasingly prevalent in community-onset infections. CTX-M-15, selected for and distributed via the globally successful E. coli ST131 clone, exemplifies how a single enzyme variant embedded in a highly fit bacterial lineage can reshape the epidemiology of urinary tract and bloodstream infections across entire continents within a decade. Carbapenemases present an even more serious clinical challenge because they hydrolyse carbapenems — agents historically reserved as the definitive last-resort treatment for gram-negative infections resistant to all other beta-lactams. Among carbapenemases, KPC variants dominate in the Americas; OXA-48 and related enzymes are prevalent across Europe, the Middle East, and North Africa; while NDM-type metallo-beta-lactamases have spread from the Indian subcontinent to achieve near-global distribution.

Other enzymatic resistance mechanisms affecting non-beta-lactam drugs include the aminoglycoside-modifying enzymes (AMEs) — acetyltransferases, phosphotransferases, and nucleotidyltransferases — each of which appends a chemical group to the aminoglycoside scaffold at a position critical for ribosomal binding, abolishing antimicrobial activity. Rifampicin inactivation by glycosyltransferases, ADP-ribosyltransferases, and monooxygenases has been described in several environmental and clinical species. Chloramphenicol acetyltransferases have long been characterised but retain importance in resource-limited settings where this drug is still deployed. The diversity and abundance of antibiotic-inactivating enzymes in both clinical isolates and environmental microbiomes constitutes what has been termed the 'resistome' — a reservoir from which further clinical resistance determinants may be recruited under selective

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

pressure. Importantly, the resistome is not confined to pathogenic bacteria; environmental organisms, including soil actinomycetes that are themselves the original producers of many antibiotic classes, harbour ancestral resistance genes whose clinical derivatives continue to emerge.

4.2 Structural Remodelling of Drug Target Sites

Where enzymatic inactivation destroys the drug, target site alteration takes a subtler approach: it preserves the integrity of the drug molecule but reconfigures the bacterial structure to which it normally binds, reducing or eliminating productive drug-target interaction while maintaining the essential cellular function. The clearest illustration of this strategy at the population level is MRSA. The mecA gene, typically carried on the staphylococcal chromosomal cassette mec (SCCmec) mobile element, encodes PBP2a — a modified penicillin-binding protein whose altered active-site geometry confers profoundly reduced affinity for virtually all beta-lactam antibiotics while retaining its transpeptidase function in cell wall cross-linking. A closely related gene, mecC, found in livestock-associated MRSA lineages, operates by the same principle.

Fluoroquinolone resistance through target site modification is mediated by substitutions within the quinolone resistance-determining regions (QRDRs) of the genes encoding DNA gyrase (gyrA, gyrB) and topoisomerase IV (parC, parE). Single QRDR mutations may raise MICs modestly, but combinations of substitutions in both enzyme pairs produce high-level resistance clinically indistinguishable from complete treatment failure. For rifampicin in Mycobacterium tuberculosis, the situation is starker still: over 95% of rifampicin-resistant TB isolates carry a substitution within an 81-base-pair hotspot region of rpoB, and many of these mutations are detectable by molecular assays, enabling rapid resistance diagnosis. Linezolid resistance arises through 23S rRNA mutations at positions 2576 and 2503, through acquisition of cfr methyltransferase genes, or through mutations in ribosomal proteins L3 and L4.

A particularly clinically consequential form of target modification is vancomycin resistance in enterococci, mediated by the vanA and vanB gene clusters. These systems reprogram cell wall biosynthesis, replacing the normal D-Ala-D-Ala terminus of peptidoglycan precursors with D-Ala-D-Lac, which has a thousand-fold reduced affinity for vancomycin. The transferability of vanA clusters on conjugative plasmids has raised the long-standing concern that vancomycin resistance could transfer from enterococci into MRSA strains — an event that has been documented in clinical isolates, though such strains have not yet achieved widespread dissemination.

4.3 Active Drug Expulsion Through Efflux Systems

Bacteria maintain a surveillance and ejection capability for toxic compounds through efflux pumps — membrane-spanning protein assemblies that harness the energy of the proton motive force or ATP hydrolysis to drive structurally diverse molecules out of the cell against a concentration gradient. Unlike enzymatic resistance mechanisms that act on specific chemical scaffolds, many efflux pumps operate with remarkable substrate promiscuity, extruding antibiotics from multiple classes simultaneously. It is this promiscuity that makes efflux pump overexpression a central driver of multidrug resistance in clinical isolates.

Five transporter superfamilies account for clinically relevant efflux-mediated resistance. The Resistance-Nodulation-Division (RND) family, confined to gram-negative bacteria, assembles into tripartite complexes spanning inner membrane, periplasm, and outer membrane that

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

discharge substrates directly into the extracellular medium. In Pseudomonas aeruginosa, the MexAB-OprM and MexXY-OprM pumps are particularly important: MexAB-OprM extrudes beta-lactams, fluoroquinolones, chloramphenicol, and macrolides, while MexXY-OprM specialises in aminoglycosides. Mutations in regulatory loci — mexR for MexAB-OprM and mexZ for MexXY-OprM — derepress pump expression, elevating MICs across drug classes simultaneously. The AcrAB-TolC system of Enterobacteriaceae is structurally and functionally analogous and has been extensively studied as both a resistance mechanism and a potential therapeutic target. In gram-positive pathogens, MFS family pumps such as NorA in S. aureus and EfmA in enterococci handle fluoroquinolones and biocides respectively.

4.4 Outer Membrane Impermeability

The outer membrane of gram-negative bacteria functions as a second permeability barrier beyond the cytoplasmic membrane, and its properties substantially influence which antibiotics can accumulate intracellularly at concentrations sufficient to inhibit growth. Hydrophilic antibiotics — including most beta-lactams, aminoglycosides, chloramphenicol, and certain fluoroquinolones — cross this barrier primarily through water-filled transmembrane protein channels called porins. Loss-of-function mutations or transcriptional downregulation of specific porin genes substantially reduce intracellular drug concentrations. In K. pneumoniae, the clinical emergence of carbapenem resistance is frequently driven not by carbapenemase acquisition alone but by a synergistic combination of porin loss with low-level KPC expression — each mechanism individually insufficient for high-level resistance, but together producing MICs that exceed any clinically achievable carbapenem concentration.

4.5 Community-Level Protection: Biofilm Architecture

When bacteria colonise a solid surface — a catheter lumen, a prosthetic valve, a debrided wound bed, or the airway epithelium of a cystic fibrosis lung — they frequently develop biofilm communities whose collective properties bear little resemblance to the planktonic growth studied in standard susceptibility testing. Within a biofilm, cells are embedded in a self-produced matrix of exopolysaccharides, extracellular DNA, and proteins. This matrix is not merely a passive scaffold; it is a dynamic structure that impedes antibiotic diffusion, binds and chemically neutralises some drug molecules, and provides mechanical resistance to shear forces. Antibiotic tolerance in biofilm organisms is characteristically 100- to 1,000-fold higher than in equivalent planktonic cultures, a property that renders standard MIC-based prescribing nearly meaningless for biofilm-associated infections.

Within the biofilm, metabolic heterogeneity is pronounced. Cells near the surface receive oxygen and nutrients relatively freely and divide at rates comparable to planktonic growth; cells in deeper layers, where oxygen is depleted and metabolic waste accumulates, grow slowly or enter reversible dormancy. Many antibiotics — including beta-lactams, fluoroquinolones, and aminoglycosides — require active cell division or specific metabolic activities to exert their lethal effects, meaning that slowly growing or dormant biofilm cells are intrinsically less vulnerable regardless of which resistance genes they carry. Biofilm physiology also dramatically accelerates horizontal gene transfer by maintaining high local cell densities and facilitating membrane contact between donors and recipients. Clinically, biofilm-associated infections on indwelling medical devices are rarely curable by antibiotic therapy alone and typically require device removal combined with prolonged systemic treatment.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026



Figure 4. Architecture of a bacterial biofilm showing the extracellular polymeric matrix, layered metabolic heterogeneity from oxygenated surface to anoxic depths, and antibiotic-tolerant persister populations.

4.6 Persister Cell Dormancy

Even within planktonic cultures exposed to bactericidal antibiotics at concentrations far exceeding the MIC, a small subpopulation — typically between one in a thousand and one in a million cells — survives treatment and resumes growth once the antibiotic is withdrawn. These persister cells are not genetically resistant; if they are isolated and retested, they exhibit the same susceptibility as the parent population. Their tolerance arises instead from a phenotypic switch into deep dormancy mediated primarily by toxin-antitoxin (TA) systems. Under conditions of metabolic stress, the antitoxin component of these regulatory pairs is proteolytically degraded, freeing the stable toxin to inhibit essential cellular processes — ribosomal translation, DNA replication, or cell division — driving the cell into a metabolically inert state from which it cannot be killed by conventional antibiotics.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

HipA/HipB, MazEF, and RelE/RelB are among the best-characterised TA modules associated with persistence, and their expression has been documented to increase in response to nutrient limitation, oxidative stress, and DNA damage. The clinical significance of persisters is considerable: they are strongly implicated in the relapsing nature of chronic infections, including recurrent urinary tract infections, persistent bacteraemia associated with intravascular catheters, and the treatment failure that characterises tuberculosis and other mycobacterial diseases. Therapeutic strategies that specifically target metabolic dormancy — by forcing persister cells out of their dormant state before antibiotic exposure, or by using drugs that kill non-dividing cells — represent an active research frontier. Recent work has demonstrated that compounds activating the TCA cycle in dormant persisters can resensitise them to aminoglycoside killing, offering a pharmacological approach to persistence eradication that bypasses the need for novel antibiotic scaffolds.

5. Genomic and Genetic Architecture of Resistance Dissemination



Figure 3. Mechanisms of horizontal gene transfer driving the dissemination of resistance determinants between bacteria: conjugation, transformation, and transduction.

The speed with which resistance phenotypes spread across bacterial populations and geographical boundaries would be impossible to explain by clonal expansion alone. The answer lies in the mobility of resistance genes — their capacity to exist on genetic elements that can be transferred between bacteria of different species, and indeed different genera, through mechanisms that require neither the death of a donor cell nor extended periods of adaptation. This horizontal genetic mobility transforms the bacterial resistome from a set of lineage-specific traits into a shared genetic commons accessible to any organism capable of receiving incoming DNA.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Plasmids are the pre-eminent vehicles of resistance gene mobilisation. These autonomously replicating circular DNA molecules range in size from a few kilobases to several hundred, and they are capable of carrying resistance cassettes conferring resistance to numerous antibiotic classes simultaneously. The co-location of multiple resistance genes on a single transferable element means that selection pressure from any one antibiotic maintains the entire resistance package in the population — a phenomenon known as co-selection. Among the most epidemiologically important plasmid families are the IncF, IncI, IncN, and IncX incompatibility groups, which frequently carry ESBL and carbapenemase genes in Enterobacteriaceae and have been identified in clinical isolates collected across multiple continents with near-identical genetic architectures, attesting to the global reach of plasmid-mediated transfer.

Transposable elements — segments of DNA flanked by terminal inverted repeats and capable of catalysed movement between genomic locations via a transposase enzyme — further accelerate resistance gene accumulation. Composite transposons, formed when two insertion sequences flank a resistance gene, can excise that gene from one replicon and insert it into another. Integrons are particularly powerful resistance gene-capturing platforms. These site-specific recombination systems maintain a library of gene cassettes that can be expressed from a common promoter and are continuously shuffled by an integrase enzyme. Class 1 integrons — the most clinically prevalent category — are virtually universally associated with gene cassettes encoding aminoglycoside-modifying enzymes, dihydropteroate synthase variants conferring sulphonamide resistance, chloramphenicol acetyltransferases, and small beta-lactamases, often combined on a single platform within a plasmid backbone.

Whole-genome sequencing (WGS) has transformed the analytical capacity available for tracking these mobile elements in real time. The reconstruction of transmission networks — tracing how a resistance plasmid or a specific high-risk clonal lineage has moved between patients, wards, hospitals, and countries — now depends on genomic epidemiology rather than on phenotypic typing methods. High-risk clones such as E. coli ST131, K. pneumoniae ST258, and MRSA clonal complex 8 have been identified and tracked using WGS and phylogenomic methods, revealing both the geographic scale of their dissemination and the specific acquisition events through which they accumulated resistance genes. Comprehensive resistance gene databases including CARD, ResFinder, and ARG-ANNOT provide the reference frameworks for systematic genomic resistance profiling from clinical sequencing data. Metagenomic approaches applied to wastewater, agricultural soils, and hospital environments are further expanding the surveillance toolkit, enabling population-level tracking of resistance gene abundance and diversity in complex microbial communities without the requirement to culture individual organisms.

6. Shortcomings of the Existing Antibiotic Toolkit

An honest appraisal of the current antibiotic armamentarium reveals constraints that operate at multiple levels simultaneously. At the molecular level, many agents that were efficacious at the time of introduction have accumulated significant resistance burdens — not as a consequence of pharmacological inadequacy, but because decades of widespread use have enriched resistant variants in both clinical and environmental settings. Therapeutic relationships that were once reliable and economical — ampicillin for E. coli urinary tract infections, trimethoprim-sulphamethoxazole for community-acquired chest infections, fluoroquinolones as empirical

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

cover for febrile neutropenia — have been eroded by resistance prevalences that now make them unsuitable as first-line choices in many clinical contexts.

Pharmacologically, several antibiotic classes carry toxicity profiles that constrain dosing and duration. The nephrotoxicity and ototoxicity of aminoglycosides requires therapeutic drug monitoring and restricts cumulative exposure. Polymyxins — resurrected as last-resort agents against extensively drug-resistant gram-negatives — carry substantial nephrotoxic and neurotoxic risk that necessitates careful dose individualisation and frequent renal function monitoring. Vancomycin, the cornerstone of MRSA therapy for decades, requires intravenous administration and monitoring to avoid renal injury, and its activity against heteroresistant MRSA with elevated vancomycin MICs within the 'susceptible' range has been the subject of sustained concern.

The structural problem underlying these individual limitations is the near-total collapse of investment in genuinely novel antibiotic drug discovery. The pharmaceutical industry's withdrawal reflects economic arithmetic rather than scientific indifference: the cost of bringing a new antibiotic through Phase I to Phase III clinical development and regulatory approval is estimated to exceed one billion US dollars, yet the commercial return on a successfully licensed antibiotic is typically a fraction of what is achievable with a chronic-disease drug whose patient population takes medication for decades rather than days. Compounding this is the paradox that an antibiotic must be used sparingly and rationally to preserve its effectiveness — precisely the usage pattern that generates the lowest revenue. Several biotechnology companies that successfully navigated clinical trials with novel antibiotics filed for bankruptcy shortly after regulatory approval, unable to achieve the revenue to service their development debt. This market failure is not self-correcting through normal competitive mechanisms, making the case for structural public intervention compelling and urgent.

7. Emerging and Innovative Therapeutic Approaches

Recognition that neither incremental modification of existing antibiotic scaffolds nor market forces alone can close the therapeutic gap has prompted a diversification of research investment across a range of approaches that differ fundamentally from conventional antibiotic development in their modes of action, their biological targets, and the nature of the selective pressure they impose on bacterial populations.

7.1 Next-Generation Antibiotics and Novel Scaffolds

Recent regulatory approvals have provided some genuinely useful additions to the therapeutic formulary even when they do not represent entirely new mechanisms. Ceftazidime-avibactam combines a third-generation antipseudomonal cephalosporin with avibactam, a diazabicyclooctane (DBO) beta-lactamase inhibitor structurally distinct from all previous inhibitors and capable of inactivating class A and D serine carbapenemases as well as class C AmpC enzymes. Its approval provided the first reliable oral and intravenous option for KPC-producing CRE in many healthcare settings. Ceftolozane-tazobactam was designed around the specific challenge of MDR P. aeruginosa, incorporating structural modifications to the cephalosporin nucleus that reduce susceptibility to the dominant AmpC beta-lactamase of this species. Imipenem-cilastatin-relebactam adds a second novel DBO inhibitor to a well-established carbapenem backbone.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Among truly novel scaffolds, omadacycline overcomes the two major tetracycline resistance mechanisms — ribosomal protection proteins and specific efflux pumps — and has received approval for community-acquired pneumonia and acute bacterial skin infections. Lefamulin is the first pleuromutilin antibiotic approved for systemic use in humans, binding the ribosomal peptidyl transferase centre at a site topographically distinct from macrolides, lincosamides, or streptogramins. Zoliflodacin, a spiropyrimidinetrione antibiotic that inhibits GyrB through a mechanism distinct from fluoroquinolone inhibition of GyrA, has completed Phase 3 trials for uncomplicated gonorrhoea — the first novel gonorrhoea-specific agent to reach this stage. Gepotidacin, another novel mechanism compound targeting bacterial type II topoisomerases at a site overlapping but structurally distinct from fluoroquinolone binding, has shown efficacy in uncomplicated urinary tract infections with activity against fluoroquinolone-resistant strains. These two agents together represent the most significant mechanistic diversification in antibacterial drug development in more than a decade.

7.2 Adjuvant Compounds That Neutralise Resistance Machinery

Rather than seeking new drugs to replace those defeated by resistance, the adjuvant strategy seeks to restore the efficacy of existing agents by disabling the molecular mechanisms that have neutralised them. The clinical template is the use of beta-lactamase inhibitors alongside beta-lactam antibiotics — a strategy that has been standard practice since clavulanate was co-formulated with amoxicillin in the early 1980s. The evolution of inhibitor chemistry has tracked the evolution of beta-lactamases: as ESBLs and carbapenemases rendered first-generation inhibitors insufficient, new chemical classes — avibactam, relebactam, nacubactam, and taniborbactam — with broader inhibitory spectra have emerged. Taniborbactam is notable as a novel bicyclic boronate that inhibits both serine beta-lactamases and class B metallo-beta-lactamases — a substrate range no single previous inhibitor could match.

Efflux pump inhibitors (EPIs) represent a conceptually elegant but technically challenging adjuvant class. Compounds such as phenylalanine-arginine beta-naphthylamide and 1-(1-naphthylmethyl)-piperazine have demonstrated that blocking RND family pumps pharmacologically can restore fluoroquinolone, tetracycline, and chloramphenicol susceptibility in resistant Pseudomonas and Enterobacteriaceae strains in vitro. The primary obstacle to clinical translation has been toxicity: first-generation EPIs interacted with mammalian efflux systems including P-glycoprotein and organic anion transporters, producing unacceptable off-target effects. Structure-activity relationship work aimed at achieving selectivity for bacterial over mammalian transporters is ongoing. Outer membrane permeabilisers, including polymyxin B nonapeptide — a cationic peptide fragment that disrupts LPS packing without the systemic toxicity of intact polymyxins — represent a related approach to sensitising gram-negative bacteria to drugs normally excluded by the outer membrane barrier.

7.3 Nanoparticle-Based Drug Delivery

The nanomedicine approach to infectious disease exploits the unique physicochemical properties of materials at the nanoscale to address limitations of conventional antibiotic delivery: poor bioavailability in target tissues, rapid renal or hepatic clearance, inability to penetrate biofilm matrices, and dose-limiting systemic toxicity. Nanocarrier platforms under active investigation span several material classes. Liposomes — vesicles enclosed by phospholipid bilayers structurally similar to bacterial membranes — can encapsulate both hydrophilic drugs in their aqueous interior and lipophilic drugs within the bilayer itself. Amikacin liposome inhalation suspension (ALIS), which delivers aminoglycoside directly into pulmonary macrophages and

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

alveolar spaces, is the first FDA-approved liposomal antibiotic and offers a paradigm for the targeted local delivery of drugs whose systemic toxicity would otherwise prohibit the concentrations required to kill intracellular or biofilm-resident pathogens.

Inorganic nanoparticles, particularly silver, zinc oxide, and copper oxide, exert antimicrobial effects through a combination of reactive oxygen species generation, direct membrane disruption by particle surface contact, and ion release — a multi-target mechanism that is inherently more difficult for bacteria to overcome through single-step mutation than a drug with a defined molecular target. The key challenge with metallic nanoparticles for systemic application is the potential for cytotoxicity to mammalian cells and for accumulation in tissues with unknown long-term consequences. Polymeric nanoparticles fabricated from PLGA, chitosan, and related biocompatible polymers offer tuneable drug release kinetics, pH-responsive payload discharge at infection sites, and the practical advantage of established large-scale manufacturing processes. Dendrimers — highly branched synthetic polymers with precisely controlled molecular architecture — represent a newer nanocarrier class whose multivalent surface chemistry allows simultaneous drug loading and targeting ligand presentation, enabling sophisticated active-targeting strategies that direct antibiotic cargo to specific bacterial cell surface components.

7.4 Bacteriophage Therapy



AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Figure 5. Bacteriophage therapy: lytic phages adsorb to and replicate within target bacteria, lysing the cell and releasing progeny phages that propagate the infection.

Bacteriophages — viruses whose exclusive hosts are bacteria — were investigated as therapeutic agents within a decade of their discovery by d'Herelle in 1917 and continued to be used clinically in Eastern Europe and the former Soviet Union throughout the antibiotic era. Renewed interest in the West was initially driven by intellectual curiosity about biological alternatives to antibiotics, but in recent years a series of compelling compassionate-use reports has given phage therapy genuine clinical momentum. The properties that make phages therapeutically attractive are well established: they replicate exponentially at the site of infection within their bacterial host, concentrating activity precisely where it is needed; they are intrinsically host-specific, leaving the commensal microbiota largely undisturbed; many carry depolymerase enzymes capable of degrading the EPS matrix of biofilms; and bacterial resistance to phage, when it arises, frequently incurs fitness costs that reduce bacterial virulence or restore antibiotic susceptibility through collateral sensitivity mechanisms

Among reported compassionate-use successes, the treatment of a pan-resistant Acinetobacter baumannii infection with an intravenous phage cocktail in San Diego in 2016 attracted particularly wide attention. Subsequent cases have described phage therapy rescue in prosthetic valve endocarditis, refractory sternal wound infections after cardiac surgery, and non-tuberculous mycobacterial lung disease in cystic fibrosis patients. The formidable challenges facing clinical development of phage products include the narrow host range of individual phage strains, the lack of regulatory frameworks designed for evolving biological therapeutics, and the difficulty of blinded controlled trial design when phage-bacterium matching is inherently patient-specific. Bacteriophage-derived endolysins — the enzymes phages use to lyse their hosts at the end of the replication cycle — offer a partially distinct therapeutic avenue, killing gram-positive bacteria with high potency and rapidity, and engineered variants extended with outer membrane-disrupting peptide domains (artilysins) have broadened their activity to gram-negative pathogens in preclinical models.

Synthetic biology advances are enabling a new generation of engineered phages with programmable host ranges, enhanced biofilm penetration, and reduced immunogenicity. Phage cocktails assembled from computationally selected candidates with complementary receptor binding profiles offer broader coverage and reduce the likelihood of rapid resistance emergence compared with single-phage preparations. Regulatory agencies including the FDA and EMA have begun engaging with phage therapy developers through adaptive trial designs and accelerated approval pathways that acknowledge the inherently personalised nature of phage-bacterium matching, though a comprehensive regulatory framework specific to phage products has yet to be formalised in most jurisdictions.

7.5 Antimicrobial Peptides and Immunomodulatory Strategies

Antimicrobial peptides (AMPs) occupy a front-line position in the innate immune defences of virtually all multicellular organisms. Human AMPs including cathelicidin LL-37, alpha- and beta-defensins, and histatins exert broad-spectrum bactericidal effects primarily by inserting into bacterial membranes and disrupting their structural integrity through pore formation, membrane thinning, or lateral phase segregation of lipid components. The appeal of AMPs as therapeutic leads is clear: their physical mechanism of action is fundamentally less susceptible to single-target resistance mutations than drugs that rely on precise interaction with a defined molecular receptor, they can be active against biofilm-embedded bacteria that tolerate conventional

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

antibiotics, and many simultaneously modulate host immune responses, potentially enhancing bacterial clearance beyond their direct bactericidal contribution.

Nevertheless, the translation of AMPs into clinical antibiotics has proven consistently difficult. Protease susceptibility reduces in vivo half-lives, haemolytic toxicity at bactericidal concentrations is a recurring concern, and synthesis costs for peptide drugs are higher than for small-molecule antibiotics. Strategies to address these limitations include substituting D-amino acids for L-amino acids in the peptide backbone to prevent recognition by peptidases, cyclisation to increase conformational rigidity and protease resistance, and conjugation to carrier nanoparticles that protect the peptide until release at infection sites. Peptidomimetics — synthetic compounds that recapitulate the topology and charge distribution of AMPs using non-peptide backbones resistant to proteolytic degradation — represent a promising direction for combining the mechanistic advantages of AMPs with more favourable pharmacokinetic profiles. Several beta-peptide and peptoid compounds have demonstrated potent activity against MRSA and MDR gram-negatives in murine infection models, with improved therapeutic indices compared to natural peptide templates.

7.6 CRISPR-Based Precision Antimicrobials



AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Figure 6. CRISPR-Cas9 as a sequence-specific antimicrobial: a guide RNA directs the Cas9 nuclease to introduce a lethal double-strand break in a defined bacterial DNA target.

The repurposing of CRISPR-Cas nuclease systems — originally characterised as bacterial adaptive immune mechanisms directed against bacteriophages — for therapeutic use against bacteria themselves represents a conceptual reversal of considerable elegance. When a CRISPR-Cas complex is programmed with a guide RNA complementary to a specific DNA sequence within a bacterial genome, it directs the Cas nuclease to that sequence and introduces a double-strand break. Bacteria lack the non-homologous end-joining repair pathways that eukaryotic cells use to survive such breaks, meaning that CRISPR-mediated chromosomal cutting is lethal in a sequence-specific and programmable manner. This enables CRISPR antimicrobials to be designed that kill only bacteria carrying a defined resistance gene or a specific pathogenic sequence, leaving susceptible commensals and resistance-free organisms entirely unharmed — a precision fundamentally unachievable with conventional broad-spectrum antibiotics.

Delivery of CRISPR components to the target bacterium in vivo is the central unsolved technical challenge. Bacteriophage-based delivery vehicles — phagemids carrying CRISPR arrays — have demonstrated proof-of-concept in animal infection models and can co-opt the host specificity of the phage to direct CRISPR payload toward the target organism. Conjugative plasmids that self-transfer CRISPR elements between bacteria offer an alternative delivery mechanism that exploits the same HGT machinery by which resistance genes spread. Beyond therapeutic applications, CRISPR-based diagnostics employing the collateral nuclease activity of Cas12 and Cas13 enzymes — which cleave non-specific reporter molecules once activated by target recognition, generating a fluorescent or colorimetric signal — are enabling point-of-care detection of resistance genes from clinical samples in under an hour, potentially transforming the speed of resistance-informed prescribing.

7.7 Host-Directed Therapy and Immunostimulatory Approaches

Host-directed therapy (HDT) seeks to modulate the host immune response to infection rather than directly targeting the pathogen. This approach is particularly compelling for infections caused by pathogens with extraordinary capacity for resistance evolution, including M. tuberculosis, where HDT could reduce the duration of antibiotic treatment required by enhancing endogenous bacterial clearance mechanisms. Vitamin D receptor agonists, which upregulate cathelicidin production in macrophages and enhance autophagy-mediated intracellular bacterial killing, have shown modest but reproducible effects in TB treatment trials. Statins, beyond their lipid-lowering effects, modulate macrophage inflammatory responses and have been associated with reduced TB mortality in observational studies, though randomised trial data remain limited.

Monoclonal antibodies targeting bacterial toxins, surface antigens, or virulence factors represent a more targeted form of HDT. Bezlotoxumab, targeting Clostridioides difficile toxin B, is the first approved antibody specifically indicated to prevent C. difficile infection recurrence — a clinical context where recurrence rates with antibiotic treatment alone can reach 25-30%. For S. aureus, multiple monoclonal antibody programmes have failed in late-stage clinical trials despite promising preclinical data, highlighting the complexity of staphylococcal immune evasion mechanisms. Passive immunotherapy using polyclonal hyperimmune immunoglobulin preparations and the emerging field of nanobody engineering — producing small, single-domain antibody fragments with superior tissue penetration and compatibility with aerosolisation for respiratory infections — represent further directions within the immunotherapy space.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

8. Machine Learning and Computational Approaches



Figure 7. Machine learning for antibiotic discovery: chemical libraries are screened by deep neural networks to rank novel antimicrobial candidate molecules.

The application of machine learning and artificial intelligence methods to infectious disease research has gained substantial traction over the past decade, driven both by the maturation of algorithmic techniques and by the expanding availability of high-quality genomic, structural, and clinical datasets on which those algorithms can be trained. In the antibiotic discovery context, the most immediate application of deep learning is in screening virtual or physical chemical libraries to identify compounds with predicted antimicrobial activity, bypassing the slow and expensive process of experimental high-throughput screening. Graph neural networks, which represent molecules as graphs of atoms and bonds rather than as fixed-length feature vectors, have proven particularly effective at capturing the structural determinants of antibiotic activity from training datasets of known antibacterial compounds.

A study published in Cell in 2020 demonstrated that a graph neural network model trained on antibacterial activity data for approximately 2,300 compounds could predict novel antibiotics from a library of over 6,000 molecules with meaningful accuracy. The top-ranked prediction was halicin, a compound found to kill drug-resistant Mycobacterium tuberculosis and pan-resistant

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Acinetobacter baumannii in mouse infection models through a mechanism involving disruption of the transmembrane electrochemical gradient — a mode of action entirely distinct from any licensed antibiotic. Subsequent work from the same group applied the approach to larger virtual chemical libraries and identified additional structurally novel antimicrobial candidates, including abaucin, a compound with selective activity against A. baumannii identified through AI-assisted screening of billions of virtual molecules.

Genotype-to-phenotype prediction — training machine learning classifiers to infer antimicrobial susceptibility from bacterial whole-genome sequences — represents another area of rapid progress. For several organism-drug combinations, including M. tuberculosis and rifampicin, S. aureus and methicillin, and E. coli and fluoroquinolones, prediction accuracy from genomic data now approaches or matches that of phenotypic susceptibility testing, with the considerable advantage that genomic data can be generated from clinical samples faster than culture-based MIC determination. Transformer architectures originally developed for natural language processing have been adapted for protein sequence analysis, enabling prediction of novel beta-lactamase variants and assessment of their likely inhibitor susceptibility profiles from sequence alone — a capability with direct relevance to anticipating clinical resistance emergence before it is detected in surveillance networks.

At the population level, forecasting models that integrate surveillance data, antibiotic consumption patterns, genomic epidemiology, and patient movement data are beginning to offer short- to medium-term predictions of emerging resistance trends, enabling healthcare systems to adjust prescribing guidelines and stewardship interventions prospectively rather than reactively. Federated learning approaches — in which model training occurs across distributed datasets held at individual institutions without raw data leaving local servers — are addressing the data sharing barriers that have historically limited the size and representativeness of training datasets for resistance prediction algorithms, with early consortia demonstrating that federated training can match or approach the performance of centralised approaches for antimicrobial susceptibility prediction tasks.

9. Prevention, Stewardship, and Systemic Control

9.1 Antimicrobial Stewardship

Antimicrobial stewardship programmes (ASPs) encompass the coordinated institutional effort to ensure that every antibiotic prescription represents the right drug, at the right dose, by the right route, for the right duration, for a diagnosis that genuinely requires antibiotic treatment. The evidence base for stewardship is now robust: systematic reviews consistently demonstrate that well-implemented ASPs reduce total antibiotic consumption by 20-40% without adverse effects on patient outcomes or mortality, and prospective audit and feedback, as well as pre-authorisation requirements for broad-spectrum agents, are the interventions most strongly supported by clinical evidence. Stewardship in the inpatient setting requires active participation from clinical pharmacists with infectious disease expertise, supported by rapid diagnostic systems that enable pathogen identification and susceptibility profiling in timeframes that can inform de-escalation from empirical broad-spectrum therapy within 24-48 hours of admission.

Community stewardship, addressing the large volume of antibiotic use in primary care settings — much of it for self-limiting viral respiratory conditions — is in some respects more challenging than hospital stewardship, given the time pressure of outpatient consultations and the

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

role of patient expectation in prescribing behaviour. Point-of-care diagnostic tests including rapid antigen tests, C-reactive protein lateral flow assays, and near-patient molecular platforms for respiratory pathogen identification have demonstrated consistent reductions in antibiotic prescribing when integrated into primary care decision-making, without adverse patient outcomes. Delayed prescribing strategies — providing a prescription with instructions to fill it only if symptoms do not improve within 48-72 hours — offer a pragmatic approach to managing patient expectations while avoiding unnecessary antibiotic exposure for self-limiting conditions.

9.2 Infection Prevention Infrastructure

No stewardship programme can fully compensate for inadequate infection prevention, because transmission of resistant organisms between patients creates the clinical infections that then demand antibiotic treatment. Hand hygiene compliance — still below recommended thresholds in many healthcare facilities despite decades of awareness campaigns — remains the single most evidence-supported measure for interrupting nosocomial transmission. Contact and droplet precautions for patients known to carry resistant pathogens, rigorous environmental decontamination with sporicidal agents, and systematic active surveillance cultures to detect colonisation before clinical infection occurs are the core institutional measures endorsed by international guidelines. The role of built-environment design in infection prevention — single-room accommodation, proximity of hand hygiene facilities to patient contact points, surface materials with reduced biofilm-supportive properties — is increasingly recognised as a structural determinant of nosocomial transmission rates that repays investment through reduced downstream antibiotic use.

9.3 The Contribution of Vaccination

Vaccines prevent bacterial infections, and preventing infections eliminates the clinical indication for antibiotic prescribing, directly reducing the consumption that selects for resistance. This antibiotic-sparing effect of immunisation is often underappreciated relative to vaccines' direct disease prevention benefit, but epidemiological analyses of pneumococcal and Hib vaccine introduction have documented significant reductions in antibiotic prescribing for respiratory tract infections in vaccinated populations, with downstream effects on antibiotic resistance rates among vaccine-targeted organisms. Vaccines against major antibiotic-resistant pathogens — S. aureus, K. pneumoniae, P. aeruginosa, E. coli, and N. gonorrhoeae — would represent high-value contributions to the resistance response, but each faces substantial immunological and developmental challenges. The successful licensure of RSV vaccines in adults has reinvigorated confidence in the technical feasibility of vaccines for pathogens previously considered poor vaccine targets, potentially offering lessons applicable to AMR-priority organisms.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

9.4 The One Health Approach and Environmental Dimensions

Figure 8. The One Health framework: human, animal, and environmental health sectors are linked by bidirectional flows of antimicrobial resistance genes.

Effective responses to antimicrobial resistance require coordinated action across human, animal, and environmental health sectors — the conceptual framework known as One Health. Agricultural antibiotic use, which accounts for a substantial proportion of global consumption, has been substantially reduced in several high-income countries following regulatory restrictions on growth-promotion use and prescribing controls in veterinary medicine, with measurable reductions in resistance prevalences in food animals and, in some analyses, in associated human infections. Low- and middle-income countries, where prophylactic and therapeutic antibiotic use in intensive livestock production continues at high levels, represent major areas where regulatory and technical capacity-building could yield significant resistance mitigation benefits.

Environmental contamination from pharmaceutical manufacturing waste — particularly from production facilities in South and Southeast Asia where antibiotic concentrations in effluent streams have been measured at levels sufficient to select for resistance in environmental bacteria — represents an underaddressed dimension of the resistance problem. Regulatory standards for antibiotic concentrations in pharmaceutical manufacturing effluents vary enormously between

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

jurisdictions and are absent in some major producing countries. International harmonisation of environmental standards for antibiotic discharge, combined with third-party auditing of supply chain sustainability claims by pharmaceutical companies, represents a policy lever that has received increasing attention from investors, procurement agencies, and regulatory bodies.

9.5 Public Engagement and Education

Persistent misconceptions about antibiotic properties and appropriate use — including the beliefs that antibiotics treat viral infections, that courses can be stopped once symptoms resolve, and that leftover antibiotics can be safely self-administered for future illnesses — continue to drive inappropriate use in many settings. Public health communication must move beyond awareness-raising toward behaviour change, using insights from health psychology and behavioural economics to address the social norms, convenience factors, and risk perceptions that shape antibiotic-seeking behaviour. Clinician communication skills training — particularly around managing patient expectations and confidently declining antibiotic requests when they are not indicated — has demonstrated effectiveness in reducing prescribing rates without diminishing patient satisfaction scores, suggesting that the assumed trade-off between good antibiotic stewardship and positive patient experience is less pronounced than practitioners often fear.

10. Persistent Challenges and Future Directions

Even a candid inventory of promising therapeutic strategies should not obscure the structural challenges that have consistently delayed the translation of scientific advances into clinical practice. For phage therapy, regulatory agencies designed to evaluate pharmaceutically defined, chemically stable products of known composition are still developing the conceptual and procedural frameworks needed to assess evolving, biological, host-specific agents whose properties change with each bacterial encounter. Clinical trial design for phage products — defining what constitutes a meaningful efficacy endpoint for a personalised therapy whose target pathogen must be characterised before treatment can begin — remains an open methodological question.

For CRISPR-based approaches, the principal bottleneck is delivery. Gene editing of human cells in vivo has advanced considerably with lipid nanoparticle systems optimised for hepatocyte targeting, but directing CRISPR components to bacterial pathogens distributed across infection foci in a living patient demands different delivery vehicles. Biosafety questions about the environmental fate of self-propagating CRISPR-carrying plasmids — whether they could transfer to off-target organisms and produce unintended consequences — will require careful evaluation before clinical deployment.

At the systems level, the economics of antibiotic development remain deeply dysfunctional. Several biotechnology companies that navigated full clinical development programmes and achieved regulatory approval for novel antibiotics have subsequently filed for insolvency. The 2020 bankruptcy of Achaogen, developer of plazomicin, was perhaps the most vivid illustration of this structural failure. Proposed remedies include revenue-decoupled pull incentive models — in which a government or international body commits to a fixed payment upon approval of a qualifying novel antibiotic regardless of sales volume — and subscription-based reimbursement arrangements in which healthcare payers pay an annual fee for access to a drug rather than a per-course price. Both models are being piloted at national level, but global harmonisation of such

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

incentives has yet to be achieved. The PASTEUR Act in the United States and the UK's antibiotic subscription pilot represent important national experiments whose outcomes will inform the design of international pull incentive mechanisms through bodies such as CARB-X and the Global Antibiotic Research and Development Partnership (GARDP).

Looking forward, several convergent trends offer grounds for measured optimism. Advances in cryo-electron microscopy and structure-based drug design are enabling the rapid visualisation of novel drug-target interactions at atomic resolution. Synthetic biology is enabling the rational design of phage cocktails and engineered phage variants with extended and programmable host ranges. The integration of microbiome science into resistance research is illuminating how the ecological disruption caused by broad-spectrum antibiotic treatment selects for resistance and predisposes patients to secondary infections. The development of rapid, portable, low-cost diagnostics — including CRISPR-based point-of-care tests — capable of providing pathogen identity and resistance gene profile in under an hour from a clinical specimen could transform prescribing from empirical to targeted in a timeframe relevant to individual patient management, directly reducing the broad-spectrum use that disproportionately drives ecological disruption and resistance selection.

11. Conclusion

Antimicrobial resistance is neither a novel problem nor one approaching resolution. It is a dynamic and escalating challenge whose trajectory, absent sustained and coordinated intervention, leads toward a post-antibiotic landscape in which routine surgical procedures, cancer chemotherapy, and the management of chronic immunosuppressed states become untenable for the want of reliable prophylactic cover. The bacterial capacity for rapid evolution, genomic plasticity, and shared genetic exchange means that resistance will always track the introduction of new drugs, and no single therapeutic innovation will resolve the fundamental evolutionary dynamic that underlies this crisis.

What research has demonstrated with increasing clarity, however, is that the biological creativity available to combat resistance is considerable. Bacteriophages, antimicrobial peptides, CRISPR nuclease systems, machine learning-guided drug discovery, nanoparticle delivery platforms, and enzymatic adjuvants each address limitations of conventional antibiotic therapy in distinct and complementary ways. None is a panacea, and each faces formidable translational challenges. But a therapeutic ecosystem that deploys these approaches strategically — in combination with one another and alongside rigorous stewardship to preserve the antibiotics already in use — offers a more resilient defence against resistant pathogens than any single agent could provide.

The scientific community's capacity to generate promising leads is not, at present, the binding constraint on progress. What is needed, and what remains incompletely delivered, is the political and economic architecture to convert scientific promise into clinical reality at the speed the situation demands: market structures that make antibiotic development financially rational, regulatory frameworks that can accommodate biological and precision-medicine approaches to antimicrobial therapy, and global surveillance systems capable of detecting emerging resistance before it establishes itself as a clinical norm. Resistance is a biological problem inseparable from human social, economic, and political choices, and only by addressing all three dimensions simultaneously will it be possible to preserve the antimicrobial efficacy on which so much of modern medicine silently depends.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Table 3. Comparative Summary of Innovative Therapeutic Strategies

Approach	Primary Mechanism	Key Advantages	Principal Limitations
Next-gen antibiotics	Novel targets or resistance-evasive scaffolds	Proven regulatory pathway; familiar clinical use model	Rapid resistance selection; high development cost
Beta-lactamase inhibitors	Inactivate serine or metallo-enzymes protecting existing drugs	Restores approved drug efficacy; established formulary model	Inhibitor-specific; spectrum gaps remain for some MBLs
Efflux pump inhibitors	Block RND/MFS efflux restoring intracellular drug accumulation	Multi-drug resensitisation from single compound	Mammalian transporter cross-reactivity; toxicity
Liposomal nanocarriers	Targeted tissue/cell delivery; biofilm penetration; reduced systemic toxicity	First approved product (ALIS); tuneable pharmacokinetics	Manufacturing complexity; regulatory nanocharacterisation
Metallic nanoparticles	ROS generation; membrane disruption; multi-target killing	Resistance evolution difficult; broad spectrum	Cytotoxicity; tissue accumulation concerns
Phage therapy	Targeted bacterial lysis; self-amplifying; biofilm disruption	Precision; microbiome sparing; anti-biofilm enzymes	Narrow host range; evolving regulatory pathway
Endolysins	Enzymatic peptidoglycan hydrolysis	Rapid killing; low resistance risk for gram-positives	Limited gram-negative penetration without engineering
Antimicrobia	Membrane	Physical	Protease susceptibility;

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

Approach	Primary Mechanism	Key Advantages	Principal Limitations
l peptides	disruption; immune modulation	mechanism resists conventional mutations	haemolytic risk; synthesis cost
CRISPR antimicrobials	Sequence-specific chromosomal cleavage; resistance gene disruption	Unprecedented sequence precision; microbiome sparing	In vivo delivery unresolved; off-target editing risk
Machine learning tools	Predict activity, resistance, optimal dosing from large datasets	Dramatically accelerates discovery and surveillance	Data quality dependence; limited prospective validation

References

1. Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0

2. O'Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Review on Antimicrobial Resistance. London: Wellcome Trust; 2016.

3. World Health Organization. Global Action Plan on Antimicrobial Resistance. Geneva: WHO Press; 2015. ISBN 9789241509763.

4. World Health Organization. WHO Priority Pathogens List for Research and Development of New Antibiotics. Geneva: WHO; 2017.

5. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: US CDC; 2019.

6. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281.

7. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42-51.

8. Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem. 2009;78:119-146.

9. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742-750.

10. Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688-702.e13.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

11. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):e00066-18.

12. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389-395.

13. Bikard D, Euler CW, Jiang W, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32(11):1146-1150.

14. Lewis K. Persister cells. Annu Rev Microbiol. 2010;64:357-372.

15. Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010;8(9):623-633.

16. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev. 2013;65(13-14):1803-1815.

17. Piddock LJ. The crisis of no new antibiotics: what is the way forward? Lancet Infect Dis. 2012;12(3):249-253.

18. Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289(1036):321-331.

19. Ventola CL. The antibiotic resistance crisis: causes and threats. P T. 2015;40(4):277-283.

20. Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011;163(1):184-194.

21. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-327.

22. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance — the need for global solutions. Lancet. 2013;382(9912):1057-1098.

23. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-168.

24. Cassini A, Hogberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015. Lancet Infect Dis. 2019;19(1):56-66.

25. van Boeckel TP, Brower C, Gilbert M, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci USA. 2015;112(18):5649-5654.

26. Theuretzbacher U, Outterson K, Engel A, Karlen A. The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020;18(5):275-285.

27. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;399(10325):629-655.

28. Woolhouse M, Ward M, van Bunnik B, Farrar J. Antimicrobial resistance in humans, livestock and the wider environment. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140083.

29. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017;177(9):1308-1315.

30. Poulikakos P, Tansarli GS, Falagas ME. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant

Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis. 2014;33(10):1675-1685.

31. Hendriksen RS, Munk P, Njage P, et al. Global monitoring of antimicrobial resistance based on metagenomics analyses of urban sewage. Nat Commun. 2019;10(1):1124.

32. Tacconelli E, Sifakis F, Harbarth S, et al. Surveillance for control of antimicrobial resistance. Lancet Infect Dis. 2018;18(3):e99-e106.

33. Schlaberg R, Chiu CY, Miller S, Procop GW, Weinstock G; IDSA Emerging Infections Committee. Validation of metagenomic next-generation sequencing tests for universal pathogen detection. Arch Pathol Lab Med. 2017;141(6):776-786.

34. Cotter PD, Ross RP, Hill C. Bacteriocins — a viable alternative to antibiotics? Nat Rev Microbiol. 2013;11(2):95-105.

35. Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018;7:212527.

36. Rello J, van Engelen TSR, Alp E, et al. Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2018;24(12):1264-1272.

37. Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019;79(3):271-289.

38. Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517(7535):455-459.

39. Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature. 2016;529(7586):336-343.

40. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol. 2007;3(9):541-548.

41. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016;352(6285):535-538.

42. Draper LA, Cotter PD, Hill C, Ross RP. The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit gram-negative bacteria. BMC Microbiol. 2013;13:212.

43. Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet. 2015;16(8):459-471.

44. Miethke M, Pieroni M, Weber T, et al. Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem. 2021;5(10):726-749.

45. Antimicrobial Resistance National Action Plans. Monitoring Global Progress on Addressing Antimicrobial Resistance. WHO/FAO/OIE Tripartite Collaboration; 2019.

46. MacNair CR, Stokes JM, Carfrae LA, et al. Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat Commun. 2018;9(1):458.

47. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29-40.

48. Bruns H, Meinhardt-Wollweber M, Rauschendorfer T, Bruns M. Characterization of resistance mechanisms in clinically relevant gram-negative bacteria by novel molecular diagnostics. Future Microbiol. 2019;14:549-563.

ISSN NUMBER: 2692 - 5206 Volume 6. No 05. MAY ,2026

49. Torres-Barcelo C, Hochberg ME. Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. 2016;24(4):249-256.

50. Antimicrobial Resistance Benchmark 2021. Access to Medicine Foundation. Amsterdam; 2021. Available at: https://accesstomedicinefoundation.org/publications/amr-benchmark-2021

51. Hobson C, Chan AN, Wright GD. The antibiotic resistome: a guide for the discovery of natural products as antimicrobial agents. Chem Rev. 2021;121(6):3464-3494.

52. Cessman M, Perez A, Ariza J, et al. Predictors of mortality in bacteraemia caused by gram-negative pathogens harbouring class B and D carbapenemases: a multicentre study. J Antimicrob Chemother. 2021;76(5):1329-1337.